Unique ID issued by UMIN | UMIN000040131 |
---|---|
Receipt number | R000045721 |
Scientific Title | Stride Management Assist Gait Training for Parkinson's Disease: An Open-Label, Randomized Controlled Study |
Date of disclosure of the study information | 2020/04/11 |
Last modified on | 2022/01/05 15:50:26 |
Gait Training using Honda Walking Assist for Parkinson's disease
HWATPD
Stride Management Assist Gait Training for Parkinson's Disease: An Open-Label, Randomized Controlled Study
SMATPD
Japan |
Parkinson's Disease
Neurology | Rehabilitation medicine | Adult |
Others
NO
To clarify the efficacy of gait training using a wearable exoskeleton stride management assist (SMA: Honda R and D Corporation, Japan) in moderately advanced Parkinson's disease (PD) patients.
Efficacy
Others
Pragmatic
Not applicable
Primary outcome is walking distance in 3-Minute Walk Test (3MWT). We measure it at baseline and at post-intervention of 10 sessions for 3 months.
Secondary outcomes are 10-Meter Walk Test, physiological cost index (PCI) in 3MWT, Berg Balance Scale, Functional Reach Test, UPDRS part III, MDS-UPDRS 3.11 (freezing of gait), Freezing of Gait Questionnaire, PDQ-39, EQ-5D-5L and gait and posture analysis using Mobile Motion Visualizer. We measure them at baseline and at post-intervention of 10 sessions for 3 months.
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
NO
YES
Institution is not considered as adjustment factor.
NO
Central registration
2
Treatment
Other |
Patients undergo over-ground gait training using SMA of 30 minutes per session, ten times for 3 months outdoors near the participants' home.
Patients undergo over-ground gait training of 30 minutes per session, ten times for 3 months near the participants' home.
Not applicable |
Not applicable |
Male and Female
We include out-patients with PD fulfilled MDS clinically established PD criteria, who are able to walk independently with/without walking aides and patients have the following conditions; 1. Hoehn and Yahr stage is 2-4 degrees in on state, 2. UPDRS Part III score is 10 points or more in on state, 3. MMSE score is not lower than 26 points, and 4. The patient does not show an unpredictable off state.
We exclude out-patients with PD fulfilled MDS clinically established PD criteria, who are unable to walk with walking aids, or patients who have the following conditions; 1. Hoehn and Yahr stage is 1 or 5 degrees in on state. 2. UPDRS Part III score is below 10 points in on state, 3. MMSE score is below 26 points, or 4. The patient shows an unpredictable off state.
14
1st name | Noriko |
Middle name | |
Last name | Kawashima |
Kawashima Neurology Clinic
Neurology
251-0038
5-13-17, Kugenuma-Matsugaoka, Fujisawa, Kanagawa
81-466-55-1358
nkawashi@pf7.so-net.ne.jp
1st name | Noriko |
Middle name | |
Last name | Kawashima |
Kawashima Neurology Clinic
Neurology
251-0038
5-13-17, Kugenuma-Matsugaoka, Fujisawa, Kanagawa
81-466-55-1358
nkawashi@pf7.so-net.ne.jp
Kawashima Neurology Clinic
Kawashima Neurology Clinic
Self funding
Ethics Committee, National Sagamihara Hospital
18-1, Sakuradai, Sagamihara, Kanagawa
+81-42-742-8311
222-rinri@mail.hosp.go.jp
NO
かわしま神経内科クリニック/Kawashima Neurology Clinic (Kanagawa)
2020 | Year | 04 | Month | 11 | Day |
Unpublished
Completed
2017 | Year | 09 | Month | 28 | Day |
2017 | Year | 09 | Month | 28 | Day |
2017 | Year | 10 | Month | 20 | Day |
2021 | Year | 11 | Month | 10 | Day |
2021 | Year | 11 | Month | 10 | Day |
2021 | Year | 11 | Month | 10 | Day |
2021 | Year | 12 | Month | 31 | Day |
2020 | Year | 04 | Month | 11 | Day |
2022 | Year | 01 | Month | 05 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045721
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |